Please assess the completion status of the following clinical trial:

Trial Title: rTMS in the Treatment of PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* primary diagnosis of PTSD as determined by a structured interview using the Mini International Neuropsychiatric Interview (MINI)~* no change in psychotropic medications within 4 weeks before the start of rTMS~* age \> 19 years and \< 70 years~* competency to give informed consent~Exclusion Criteria:~* any non-fixed metal object or implant (including cochlear implants) in brain, skull, scalp, or neck within 30 cm of the magnetic rTMS coil~* implantable devices, including cardiac pacemakers and defibrillators~* other contraindications to rTMS, including history of seizures (except childhood febrile seizures) or recent and unexplained syncope, first-degree relative with a history of epilepsy, treatment with a medication known to substantially decrease the seizure threshold, or pregnancy~* psychiatric diagnoses of psychosis or psychotic disorder (including psychotic depression), bipolar type I disorder, or organic mental disorders~* substance abuse/dependence within the past 3 months~* active suicidal risk as judged by the clinician~* borderline or antisocial personality disorder~* acute medical illness, including cancer~* any significant central nervous system disorder, such as brain mass, stroke, etc.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low-frequency (1 Hz) rTMS (Type: ACTIVE_COMPARATOR): Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
- High-frequency (10 Hz) rTMS (Type: ACTIVE_COMPARATOR): High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
- Sham rTMS (Type: PLACEBO_COMPARATOR): Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.

Based on this trial design, predict the completion outcome and termination type (if applicable).